AVM
DNLI icon

Arch Venture Management’s Denali Therapeutics DNLI Stock Holding History

Arch Venture Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-381,249
Closed -$7.82M – 10
2024
Q1 		$7.82M Hold
381,249
– – 9.75% 4
2023
Q4 		$8.18M Sell
381,249
-312,500
-45% -$6.19M 5% 4
2023
Q3 		$14.3M Hold
693,749
– – 9.3% 4
2023
Q2 		$20.5M Sell
693,749
-1,875,000
-73% -$52.7M 12.64% 4
2023
Q1 		$59.2M Sell
2,568,749
-1,100,000
-30% -$30.3M 28.57% 2
2022
Q4 		$102M Hold
3,668,749
– – 26.13% 1
2022
Q3 		$113M Sell
3,668,749
-1,500,000
-29% -$48.8M 14.6% 3
2022
Q2 		$152M Buy
+5,168,749
New +$135M 18.54% 3

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $29.7B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return